CL2013000732A1 - Compuestos derivados de analogos de buprenorfina, con actividad como agonistas y/o antagonistas de receptores opioides; composicion que los comprende; su metodo de preparacion; y su uso para el tratamiento o prevencion del dolor o constipacion. - Google Patents

Compuestos derivados de analogos de buprenorfina, con actividad como agonistas y/o antagonistas de receptores opioides; composicion que los comprende; su metodo de preparacion; y su uso para el tratamiento o prevencion del dolor o constipacion.

Info

Publication number: CL2013000732A1
Authority: CL; Chile
Prior art keywords: constipation; agonists; pain; prevention; activity
Prior art date: 2010-09-21

Application number

CL2013000732A

Other languages

English (en)

Spanish (es)

Inventor

Donald J Kyle

Laykea Tafesse

Original Assignee

Purdue Pharma Lp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-09-21

Filing date

2013-03-18

Publication date

2013-07-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44903285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013000732(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-03-18 Application filed by Purdue Pharma Lp filed Critical Purdue Pharma Lp

2013-07-26 Publication of CL2013000732A1 publication Critical patent/CL2013000732A1/es

Links

206010010774 Constipation Diseases 0.000 title abstract 2
229940123257 Opioid receptor antagonist Drugs 0.000 title abstract 2
239000000556 agonist Substances 0.000 title abstract 2
RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical class C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 title abstract 2
150000001875 compounds Chemical class 0.000 title abstract 2
238000000034 method Methods 0.000 title abstract 2
230000002265 prevention Effects 0.000 title abstract 2

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
- C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
- C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CL2013000732A 2010-09-21 2013-03-18 Compuestos derivados de analogos de buprenorfina, con actividad como agonistas y/o antagonistas de receptores opioides; composicion que los comprende; su metodo de preparacion; y su uso para el tratamiento o prevencion del dolor o constipacion. CL2013000732A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US38491210P	2010-09-21	2010-09-21
US201161503674P	2011-07-01	2011-07-01

Publications (1)

Publication Number	Publication Date
CL2013000732A1 true CL2013000732A1 (es)	2013-07-26

Family

ID=44903285

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2013000732A CL2013000732A1 (es)	2010-09-21	2013-03-18	Compuestos derivados de analogos de buprenorfina, con actividad como agonistas y/o antagonistas de receptores opioides; composicion que los comprende; su metodo de preparacion; y su uso para el tratamiento o prevencion del dolor o constipacion.

Country Status (34)

Country	Link
US (1)	US9221831B2 (sr)
EP (1)	EP2619212B1 (sr)
JP (2)	JP5977240B2 (sr)
KR (2)	KR101630912B1 (sr)
CN (2)	CN105399751A (sr)
AR (1)	AR083062A1 (sr)
AU (1)	AU2011306644B2 (sr)
CA (1)	CA2810356C (sr)
CL (1)	CL2013000732A1 (sr)
CO (1)	CO6690803A2 (sr)
CR (1)	CR20130129A (sr)
CY (1)	CY1117227T1 (sr)
DK (1)	DK2619212T3 (sr)
DO (1)	DOP2013000060A (sr)
EA (1)	EA201390422A1 (sr)
EC (1)	ECSP13012543A (sr)
ES (1)	ES2566828T3 (sr)
HR (1)	HRP20160281T1 (sr)
HU (1)	HUE027195T2 (sr)
ME (1)	ME02367B (sr)
MX (1)	MX2013003354A (sr)
NI (1)	NI201300032A (sr)
NZ (1)	NZ609200A (sr)
PE (1)	PE20140020A1 (sr)
PH (1)	PH12013500530A1 (sr)
PL (1)	PL2619212T3 (sr)
RS (1)	RS54579B1 (sr)
SG (1)	SG188300A1 (sr)
SI (1)	SI2619212T1 (sr)
SM (1)	SMT201600088B (sr)
TW (2)	TW201242968A (sr)
UY (1)	UY33618A (sr)
WO (1)	WO2012038813A1 (sr)
ZA (1)	ZA201301217B (sr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8852638B2 (en)	2005-09-30	2014-10-07	Durect Corporation	Sustained release small molecule drug formulation
ES2562878T3 (es)	2007-05-25	2016-03-08	Indivior Uk Limited	Formulaciones de liberación sostenida de compuestos de risperidona
GB2513060B (en)	2010-06-08	2015-01-07	Rb Pharmaceuticals Ltd	Microparticle buprenorphine suspension
US9272044B2 (en)	2010-06-08	2016-03-01	Indivior Uk Limited	Injectable flowable composition buprenorphine
EP2992877A1 (en)	2010-06-15	2016-03-09	Grünenthal GmbH	Pharmaceutical combination for the treatment of pain
KR20140033377A (ko)	2011-05-10	2014-03-18	길리애드 사이언시즈, 인코포레이티드	나트륨 채널 조절제로서의 융합된 헤테로시클릭 화합물
NO3175985T3 (sr)	2011-07-01	2018-04-28
UY34171A (es)	2011-07-01	2013-01-31	Gilead Sciences Inc	Compuestos heterocíclicos fusionados como moduladores del canal iónico
EP2788358B1 (en)	2011-12-08	2018-08-29	Purdue Pharma LP	Quaternized buprenorphine analogs
US9315514B2 (en) *	2012-08-27	2016-04-19	Rhodes Technologies	1,3-dioxanomorphides and 1,3-dioxanocodides
EP2917182B1 (en)	2012-11-09	2018-01-03	Purdue Pharma LP	Benzomorphan analogs and the use thereof
WO2014087226A1 (en) *	2012-12-07	2014-06-12	Purdue Pharma L.P.	Buprenorphine analogs as opiod receptor modulators
JP6182620B2 (ja)	2013-01-31	2017-08-16	パーデュー、ファーマ、リミテッド、パートナーシップ	ベンゾモルファン類似体およびその使用
US8969358B2 (en) *	2013-03-15	2015-03-03	Purdue Pharma L.P.	Buprenorphine analogs
US20160333020A1 (en) *	2013-12-26	2016-11-17	Purdue Pharma L.P.	7-beta analogs of orvinols
WO2015097545A1 (en)	2013-12-26	2015-07-02	Purdue Pharma L.P.	Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans
EP3087057A4 (en)	2013-12-26	2017-06-28	Purdue Pharma LP	Ring-contracted morphinans and the use thereof
WO2015097548A1 (en) *	2013-12-26	2015-07-02	Purdue Pharma L.P.	7-beta-alkyl analogs of orvinols
WO2015097547A1 (en)	2013-12-26	2015-07-02	Purdue Pharma L.P.	10-substituted morphinan hydantoins
WO2015099863A1 (en)	2013-12-27	2015-07-02	Purdue Pharma L.P.	6-substituted and 7-substituted morphinan analogs and the use thereof
GB201404139D0 (en)	2014-03-10	2014-04-23	Rb Pharmaceuticals Ltd	Sustained release buprenorphine solution formulations
CA2950567A1 (en)	2014-05-27	2015-12-03	Purdue Pharma L.P.	Spirocyclic morphinans and use thereof
MA40171A (fr)	2014-06-13	2017-04-19	Purdue Pharma Lp	Dérivés d'azamophinan et leur utilisation
MA41125A (fr)	2014-12-05	2017-10-10	Purdue Pharma Lp	Dérivés de 6.7-cyclomorphinane et leur utilisation
EP3368038A4 (en) *	2015-10-26	2019-04-10	Orphomed, Inc.	BUPRENORPHINE ETHYLENE GLYCOL ETHER
HUE061547T2 (hu) *	2016-03-22	2023-07-28	Helsinn Healthcare Sa	Aszimmetrikus benzolszulfonil-karbamid-származékok és gyógyászati alkalmazásuk
WO2018125716A1 (en)	2017-01-02	2018-07-05	Purdue Pharma L.P.	Morphinan derivatives and use thereof
WO2018211331A1 (en) *	2017-05-19	2018-11-22	Evolva Sa	Preparation of buprenorphine
JP2021104932A (ja) *	2018-03-30	2021-07-26	日本ケミファ株式会社	モルヒナン誘導体の製造方法
EP4577204A1 (en) *	2022-08-23	2025-07-02	Virginia Commonwealth University	Multiple targeting opioid receptor ligands as novel analgesics with minimum abuse liability
EP4688749A2 (en) *	2023-04-04	2026-02-11	Board of Regents, The University of Texas System	Methods of synthesizing 14-beta-aminomorphans and salts thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1136764A (en) *	1965-08-13	1968-12-18	Reckitt & Sons Ltd	Derivatives of thebaine and oripavine
ES2226129T3 (es)	1997-05-30	2005-03-16	Banyu Pharmaceutical Co., Ltd.	Derivados de 2-0x0imidazol.
NZ507760A (en)	1998-03-26	2002-10-25	Japan Tobacco Inc	Amide derivatives and nociceptin antagonists
JP2004538256A (ja)	2001-03-02	2004-12-24	ユーロ−セルティーク，エス．エイ．	Ｎ−ブト−３−エチル＝ノルブプレノルフィン及び使用方法
US6740641B2 (en)	2001-07-27	2004-05-25	Euro-Celtique, S.A.	Sugar derivatives of hydromorphone, dihydromorphine and dihydromorphine, compositions thereof and uses for treating or preventing pain
PT1543010E (pt)	2002-09-25	2007-07-26	Euro Celtique Sa	Hidromorfonas n-substituídas e a sua utilização
EP1554290B1 (en)	2002-10-25	2009-09-30	Euro-Celtique S.A.	Analogs and prodrugs of buprenorphine
US7202259B2 (en)	2002-11-18	2007-04-10	Euro-Celtique S.A.	Therapeutic agents useful for treating pain
US6958398B1 (en)	2002-12-30	2005-10-25	Euro-Celtique S.A.	Methods for making thebaine or its acid salts
ES2433118T3 (es)	2006-11-01	2013-12-09	Purdue Pharma Lp	Compuestos de fenilpropionamida y uso de los mismos
GB2447014A (en) *	2007-03-01	2008-09-03	Reckitt Benckiser Healthcare	Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
CN101878214A (zh)	2007-11-30	2010-11-03	普渡制药公司	苯并吗啡烷化合物
ES2449222T3 (es) *	2008-07-30	2014-03-18	Purdue Pharma Lp	Análogos de buprenorfina
US9133131B2 (en)	2011-11-15	2015-09-15	Purdue Pharma L.P.	Pyrimidine diol amides as sodium channel blockers
EP2788358B1 (en)	2011-12-08	2018-08-29	Purdue Pharma LP	Quaternized buprenorphine analogs
AR091027A1 (es)	2012-05-11	2014-12-30	Purdue Pharma Lp	Analogos de benzomorfano y el usos de estos
US9315514B2 (en)	2012-08-27	2016-04-19	Rhodes Technologies	1,3-dioxanomorphides and 1,3-dioxanocodides
EP2917182B1 (en)	2012-11-09	2018-01-03	Purdue Pharma LP	Benzomorphan analogs and the use thereof
WO2014087226A1 (en)	2012-12-07	2014-06-12	Purdue Pharma L.P.	Buprenorphine analogs as opiod receptor modulators
EP2931724B1 (en)	2012-12-14	2017-01-25	Purdue Pharma LP	Pyridonemorphinan analogs and biological activity on opioid receptors
WO2014091297A1 (en)	2012-12-14	2014-06-19	Purdue Pharma L.P.	Spirocyclic morphinans and their use
ES2623262T3 (es)	2012-12-14	2017-07-10	Purdue Pharma Lp	Derivados de morfinano que contienen nitrógeno y el uso de los mismos
US8946255B2 (en)	2012-12-28	2015-02-03	Purdue Pharma L.P.	Substituted morphinans and the use thereof
WO2014102587A1 (en)	2012-12-28	2014-07-03	Purdue Pharma L.P.	7,8-cyclicmorphinan analogs
JP6182620B2 (ja)	2013-01-31	2017-08-16	パーデュー、ファーマ、リミテッド、パートナーシップ	ベンゾモルファン類似体およびその使用
US8969358B2 (en)	2013-03-15	2015-03-03	Purdue Pharma L.P.	Buprenorphine analogs
WO2015097546A1 (en)	2013-12-26	2015-07-02	Purdue Pharma L.P.	Propellane-based compounds and their use as opioid receptor modulators
WO2015097547A1 (en)	2013-12-26	2015-07-02	Purdue Pharma L.P.	10-substituted morphinan hydantoins
US20160333020A1 (en)	2013-12-26	2016-11-17	Purdue Pharma L.P.	7-beta analogs of orvinols
WO2015097548A1 (en)	2013-12-26	2015-07-02	Purdue Pharma L.P.	7-beta-alkyl analogs of orvinols
WO2015099863A1 (en)	2013-12-27	2015-07-02	Purdue Pharma L.P.	6-substituted and 7-substituted morphinan analogs and the use thereof
EP3089978B1 (en)	2013-12-30	2018-08-29	Purdue Pharma L.P.	Pyridone-sulfone morphinan analogs as opioid receptor ligands

2011
- 2011-09-20 ES ES11776855.6T patent/ES2566828T3/es active Active
- 2011-09-20 SI SI201130750T patent/SI2619212T1/sl unknown
- 2011-09-20 AU AU2011306644A patent/AU2011306644B2/en not_active Ceased
- 2011-09-20 CN CN201510733006.4A patent/CN105399751A/zh active Pending
- 2011-09-20 KR KR1020137009943A patent/KR101630912B1/ko not_active Expired - Fee Related
- 2011-09-20 KR KR20157004529A patent/KR20150027315A/ko not_active Withdrawn
- 2011-09-20 CN CN2011800450775A patent/CN103154000A/zh active Pending
- 2011-09-20 PH PH1/2013/500530A patent/PH12013500530A1/en unknown
- 2011-09-20 UY UY0001033618A patent/UY33618A/es unknown
- 2011-09-20 MX MX2013003354A patent/MX2013003354A/es not_active Application Discontinuation
- 2011-09-20 US US13/825,241 patent/US9221831B2/en active Active
- 2011-09-20 DK DK11776855.6T patent/DK2619212T3/en active
- 2011-09-20 CA CA2810356A patent/CA2810356C/en not_active Expired - Fee Related
- 2011-09-20 WO PCT/IB2011/002208 patent/WO2012038813A1/en not_active Ceased
- 2011-09-20 AR ARP110103431A patent/AR083062A1/es unknown
- 2011-09-20 EA EA201390422A patent/EA201390422A1/ru unknown
- 2011-09-20 EP EP11776855.6A patent/EP2619212B1/en active Active
- 2011-09-20 ME MEP-2016-38A patent/ME02367B/me unknown
- 2011-09-20 RS RS20160119A patent/RS54579B1/sr unknown
- 2011-09-20 HR HRP20160281TT patent/HRP20160281T1/hr unknown
- 2011-09-20 JP JP2013529723A patent/JP5977240B2/ja not_active Expired - Fee Related
- 2011-09-20 PL PL11776855.6T patent/PL2619212T3/pl unknown
- 2011-09-20 SG SG2013014113A patent/SG188300A1/en unknown
- 2011-09-20 PE PE2013000548A patent/PE20140020A1/es not_active Application Discontinuation
- 2011-09-20 NZ NZ609200A patent/NZ609200A/en not_active IP Right Cessation
- 2011-09-20 HU HUE11776855A patent/HUE027195T2/en unknown
- 2011-09-21 TW TW100133950A patent/TW201242968A/zh unknown
- 2011-09-21 TW TW102147960A patent/TW201422621A/zh unknown
2013
- 2013-02-18 ZA ZA2013/01217A patent/ZA201301217B/en unknown
- 2013-03-18 CL CL2013000732A patent/CL2013000732A1/es unknown
- 2013-03-20 NI NI201300032A patent/NI201300032A/es unknown
- 2013-03-20 DO DO2013000060A patent/DOP2013000060A/es unknown
- 2013-03-21 CR CR20130129A patent/CR20130129A/es not_active Application Discontinuation
- 2013-04-05 EC ECSP13012543 patent/ECSP13012543A/es unknown
- 2013-04-18 CO CO13100225A patent/CO6690803A2/es unknown
2015
- 2015-11-19 JP JP2015226945A patent/JP2016102115A/ja not_active Withdrawn
2016
- 2016-03-04 CY CY20161100187T patent/CY1117227T1/el unknown
- 2016-03-24 SM SM201600088T patent/SMT201600088B/xx unknown

Also Published As

Publication number	Publication date
RS54579B1 (sr)	2016-06-30
SG188300A1 (en)	2013-04-30
SI2619212T1 (sl)	2016-04-29
JP2016102115A (ja)	2016-06-02
CA2810356A1 (en)	2012-03-29
JP5977240B2 (ja)	2016-08-24
UY33618A (es)	2012-03-30
KR101630912B1 (ko)	2016-06-15
NI201300032A (es)	2014-01-13
AU2011306644B2 (en)	2015-07-02
PE20140020A1 (es)	2014-01-31
ECSP13012543A (es)	2013-06-28
EA201390422A1 (ru)	2014-01-30
SMT201600088B (it)	2016-04-29
NZ609200A (en)	2015-01-30
HRP20160281T1 (hr)	2016-04-08
PL2619212T3 (pl)	2016-09-30
KR20150027315A (ko)	2015-03-11
CY1117227T1 (el)	2017-04-05
JP2013543488A (ja)	2013-12-05
KR20130097210A (ko)	2013-09-02
DK2619212T3 (en)	2016-03-21
HK1187045A1 (en)	2014-03-28
CN103154000A (zh)	2013-06-12
EP2619212A1 (en)	2013-07-31
CR20130129A (es)	2013-08-29
HUE027195T2 (en)	2016-10-28
US9221831B2 (en)	2015-12-29
EP2619212B1 (en)	2016-01-06
AR083062A1 (es)	2013-01-30
ME02367B (me)	2016-06-20
TW201242968A (en)	2012-11-01
MX2013003354A (es)	2013-06-24
US20140057931A1 (en)	2014-02-27
AU2011306644A1 (en)	2013-04-11
ES2566828T3 (es)	2016-04-15
CA2810356C (en)	2016-06-14
ZA201301217B (en)	2013-09-25
DOP2013000060A (es)	2013-04-30
TW201422621A (zh)	2014-06-16
CO6690803A2 (es)	2013-06-17
PH12013500530A1 (en)	2017-08-09
WO2012038813A1 (en)	2012-03-29
CN105399751A (zh)	2016-03-16

Publication	Publication Date	Title
CL2013000732A1 (es)	2013-07-26	Compuestos derivados de analogos de buprenorfina, con actividad como agonistas y/o antagonistas de receptores opioides; composicion que los comprende; su metodo de preparacion; y su uso para el tratamiento o prevencion del dolor o constipacion.
CL2015003290A1 (es)	2016-06-17	Nuevos agonistas del receptor de somatostatina subtipo 4 (sstr4).
CR20150296A (es)	2015-08-10	Novedosos derivados de bencimidazol como antagonistas de ep4
CO6771417A2 (es)	2013-10-15	Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
CL2012000921A1 (es)	2012-09-14	Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
UY32327A (es)	2010-03-26	Antagonistas de receptores de ácido lisofosfatídico
CO6400170A2 (es)	2012-03-15	Agosnistas y antagonistas del receptor s1p5 y métodos de uso de los mismos
CL2013001677A1 (es)	2013-12-27	Compuestos derivados de azabiciclo[3.2.1]octano; agonista del receptor x fernesoide (fxr); proceso para preparar los compuestos; compuesto intermediario; composicion farmaceutica y combinacion farmaceutica que comporenden un compuesto; y uso de los compuestos en la preparacion de medicamentos para el tratamiento de dislipidemia.
CO7400870A2 (es)	2015-09-30	Compuestos derivadios de quinuclidina con actividad antagonista de los receptores muscarínicos y actividad agonista del receptor beta2 adrenérgico
ECSP12012270A (es)	2012-11-30	Compuestos de pirazol como inhibidores del receptor sigma
MY163055A (en)	2017-08-15	Polycyclic antagonists of lysophosphatidic acid receptors
CL2012003745A1 (es)	2013-05-31	Compuestos derivados de aminopirazoloquinazolinas, como inhibidores frente a la actividad fosforilante del receptor igf-1 localizado en membranas celulares; preparacion farmaceutica que los contiene; y su uso en el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
CL2015002202A1 (es)	2016-04-29	Benzamidas sustituidas con actividad hacia receptores ep4.
ECSP13012519A (es)	2013-05-31	Compuestos sustituidos de benzamida
CL2017002017A1 (es)	2018-04-13	Compuestos con actividad antagonista de los receptoresmuscarínicos y actividad agonista del receptor beta2 adrenérgico
DOP2014000098A (es)	2014-07-31	2-tiopirimidinonas
UY32734A (es)	2010-11-30	Compuestos agonistas del receptor esfingosina 1-fosfato
BR112015012720A2 (pt)	2017-07-11	derivados de feniletilpiridina como inibidores de pde4
UY35906A (es)	2015-07-31	Novedosos derivados de bencimidazol como ligandos de ep4
MX2017005484A (es)	2017-10-20	Compuestos antagonistas del receptor de dopamina d3.
CR20140257A (es)	2014-07-15	Nuevos 2h-indazoles como antagonistas del receptor ep2
MX2015011536A (es)	2016-05-31	Nuevos antagonistas de receptores trpa1 de sulfamidas.
MX2017016939A (es)	2018-11-09	Novedosas antagonistas 5-ht2.
CL2014001862A1 (es)	2014-11-14	Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia.
MX2017015047A (es)	2018-04-11	Compuestos que tienen actividad antagonista del receptor muscarinico y actividad agonista del receptor beta2 adrenergico.